Bruce Steel

CEO & Director at Equillium

Bruce is a co-founder, Director, and President and Chief Executive Officer of Equillium. He is also the founder and Managing Director of BioMed Ventures, the strategic investment arm of BioMed Realty. Since founding BioMed Ventures, Bruce has directed investments in over 30 biotechnology companies including Auspex, AnaptysBio, NeoTract and Receptos. Prior to co-founding Equillium, Bruce was co-founder and CEO of Rincon Pharmaceuticals, a genetic engineering biotechnology company, until its acquisition in 2008; previously he was Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences. Bruce serves on the Board of Directors of Breathe Technologies and Aegea Medical, and is a board observer for a number of other private companies. Bruce received his Bachelor of Arts degree from Dartmouth College and Master of Business Administration degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.

Roles

  • CEO & Director

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.